|
시장보고서
상품코드
1983315
혈액 악성 종양 시장 : 유형별, 연령층별, 치료법별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별Hematologic Malignancies Market, By Type, By Age Group, By Treatment Modality, By Route of Administration, By Distribution Channel, By End User, By Geography |
||||||
혈액 악성 종양 시장은 2026년에 900억 2,000만 달러로 추정되고 있으며, 2033년까지 1,796억 4,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 10.2%로 성장할 것으로 전망되고 있습니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준연도 | 2025년 | 시장 규모(2026년) | 900억 2,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간의 CAGR(2026-2033년) | 10.20% | 예측 금액(2033년) | 1,796억 4,000만 달러 |
세계 혈액악성종양 시장은 종양 치료 분야에서 중요한 부문으로 백혈병, 림프종, 다발성골수종 등 다양한 혈액암을 포괄하는 시장입니다. 이러한 악성 종양은 조혈 조직에서 유래하며 주로 골수, 림프절 및 기타 림프계 구성 요소에 영향을 미칩니다. 이 시장은 특히 고령화 인구의 질병 유병률 증가와 진단 기술 및 치료법의 획기적인 발전에 힘입어 크게 성장하고 있습니다.
CAR-T 세포치료제, 모노클로널 항체, 표적치료제 등 혁신적인 치료법은 환자 예후에 혁명을 일으키고 제약회사에 새로운 수입원을 창출하고 있습니다. 이 시장에는 화학요법, 면역요법, 줄기세포 이식, 그리고 새로운 정밀의료 솔루션 등 다양한 치료 접근법이 포함됩니다. 의료비 증가, 전문 종양 의료에 대한 접근성 향상, 조기 발견 능력의 향상은 시장 확대를 더욱 촉진하고 있습니다. 또한 유전자 프로파일링과 바이오마커 식별에 기반한 맞춤형 의료 접근법의 개발은 새로운 치료의 길을 열었습니다. 이 시장의 복잡성은 다양한 질환의 아형, 다양한 치료 프로토콜, 효능을 향상시키는 병용요법의 출현으로 특징지어지며, 광범위한 종양학 시장 내에서 고부가가치 부문으로 자리매김하고 있습니다.
시장 역학
세계 혈액 악성 종양 시장은 몇 가지 주요 촉진요인에 의해 견인되고 있으며, 이는 전반적으로 견고한 성장 궤도를 주도하고 있습니다. 주요 촉진요인은 전 세계 혈액암 발병률 증가, 특히 고령층에서의 혈액암 발병률 증가에 기인하며, 고령화 사회로의 인구통계학적 변화가 질병 유병률 증가에 기여하고 있습니다. 차세대 염기서열 분석, 유세포분석, 분자 검사 등 진단 기술의 발전으로 질병의 조기 발견과 정확한 특성 평가가 가능해져 적시에 치료적 개입이 가능해졌습니다.
혁신적인 치료법, 특히 CAR-T 세포치료제, 이중특이성 항체, 체크포인트 억제제의 획기적인 개발은 환자의 예후를 획기적으로 개선하고 큰 시장 가치를 창출하고 있습니다. 신흥 시장의 의료 인프라 구축과 전 세계 의료비 증가로 인해 환자들이 전문적인 치료를 받을 수 있는 기회가 확대되고 있습니다. 그러나 시장에는 심각한 제약도 존재합니다. 특히 CAR-T 치료의 경우 환자 1인당 40만 달러가 넘는 경우도 있으며, 새로운 치료법에 따른 매우 높은 비용이 의료제도와 환자들에게 경제적 부담으로 작용하고 있습니다. 복잡한 세포치료제나 생물제제에 대한 엄격한 규제 승인 절차는 시장 진입까지 긴 개발 기간과 많은 투자를 필요로 하는 경우가 많습니다.
또한 치료 프로토콜의 복잡성과 전문 의료시설 및 훈련된 인력의 필요성이 특정 지역에서의 광범위한 보급을 제한하고 있습니다. 이러한 어려움에도 불구하고 안전성 프로파일이 개선된 차세대 치료제의 개발, 질병의 초기 단계에 대한 치료 적응증 확대, 치료 효과를 높이면서 개별 약제 비용과 치료 기간을 단축할 수 있는 병용요법의 잠재적 확대 등 큰 기회가 존재합니다.
이 보고서의 주요 특징
- 세계의 혈액악성종양 시장을 상세하게 분석하고, 2025년을 기준 연도로 하여 예측기간(2026-2033년) 시장 규모와 CAGR을 조사하여 전해드립니다.
- 또한 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요 인사이트을 제공합니다.
- 이 보고서는 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 혈액 악성 종양 시장의 주요 기업 개요을 제공합니다.
- 이 보고서의 인사이트을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 혈액 악성 종양 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 혈액 악성 종양 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 혈액 악성 종양 시장 : 유형별(2021-2033년)
제5장 세계의 혈액 악성 종양 시장 : 연령층별(2021-2033년)
제6장 세계의 혈액 악성 종양 시장 : 치료법별(2021-2033년)
제7장 세계의 혈액 악성 종양 시장 : 투여 경로별(2021-2033년)
제8장 세계의 혈액 악성 종양 시장 : 유통 채널별(2021-2033년)
제9장 세계의 혈액 악성 종양 시장 : 최종사용자별(2021-2033년)
제10장 세계의 혈액 악성 종양 시장 : 지역별(2021-2033년)
제11장 경쟁 구도
제12장 애널리스트의 제안
제13장 참고 문헌 및 분석 방법
KSA 26.04.23Hematologic Malignancies Market is estimated to be valued at USD 90.02 Bn in 2026 and is expected to reach USD 179.64 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 90.02 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.20% | 2033 Value Projection: | USD 179.64 Bn |
The global hematologic malignancies market represents a critical segment within the oncology therapeutics landscape, encompassing a diverse range of blood cancers including leukemia, lymphoma, and multiple myeloma. These malignancies originate in the blood-forming tissues, primarily affecting the bone marrow, lymph nodes, and other components of the lymphatic system. The market has witnessed substantial growth driven by increasing disease prevalence, particularly among aging populations, coupled with significant advancements in diagnostic technologies and therapeutic interventions.
Innovative treatment modalities such as CAR-T cell therapies, monoclonal antibodies, and targeted therapies have revolutionized patient outcomes, creating new revenue streams for pharmaceutical companies. The market encompasses various therapeutic approaches including chemotherapy, immunotherapy, stem cell transplantation, and novel precision medicine solutions. Rising healthcare expenditure, improved access to specialized oncology care, and enhanced early detection capabilities have further propelled market expansion. Additionally, the development of personalized medicine approaches based on genetic profiling and biomarker identification has opened new therapeutic avenues. The market's complexity is characterized by diverse disease subtypes, varying treatment protocols, and the emergence of combination therapies that offer improved efficacy profiles, positioning it as a high-value segment within the broader oncology market.
Market Dynamics
The global hematologic malignancies market is propelled by several key drivers that collectively fuel its robust growth trajectory. The primary driver stems from the increasing global incidence of blood cancers, particularly among elderly populations, with demographic shifts toward aging societies worldwide contributing to higher disease prevalence rates. Technological advancements in diagnostics, including next-generation sequencing, flow cytometry, and molecular testing, enable earlier detection and precise disease characterization, facilitating timely therapeutic interventions.
The revolutionary development of innovative therapies, particularly CAR-T cell treatments, bispecific antibodies, and checkpoint inhibitors, has dramatically improved patient outcomes and created substantial market value. Growing healthcare infrastructure in emerging markets and increased healthcare spending globally have expanded patient access to specialized treatments. However, the market faces significant restraints including the extremely high costs associated with novel therapies, particularly CAR-T treatments that can exceed USD 400,000 per patient, creating affordability challenges for healthcare systems and patients. Stringent regulatory approval processes for complex cellular therapies and biologics often result in lengthy development timelines and substantial investment requirements before market entry.
Additionally, the complexity of treatment protocols and the need for specialized healthcare facilities and trained personnel limit widespread adoption in certain regions. Despite these challenges, substantial opportunities exist in the development of next-generation therapies with improved safety profiles, the expansion of treatment applications to earlier disease stages, and the growing potential for combination therapies that enhance therapeutic efficacy while potentially reducing individual drug costs and treatment duration.
Key Features of the Study
- This report provides in-depth analysis of the global hematologic malignancies market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global hematologic malignancies market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Bristol-Myers Squibb, Roche, Novartis, AbbVie, Amgen, Celgene, Gilead Sciences, Johnson & Johnson, Sanofi, Merck & Co., Pfizer, Eli Lilly and Company, Takeda Pharmaceutical Company, GSK, and Regeneron Pharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global hematologic malignancies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hematologic malignancies market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2021 - 2033)
- Leukemia
- Acute Leukemias
- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Leukemias
- Chronic Myeloid Leukemia (CML)
- Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Others (Hairy Cell Leukemia, etc.)
- Lymphoma
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma (NHL)
- Plasma Cell Dyscrasias
- Multiple Myeloma
- Smoldering Multiple Myeloma
- Others (Plasma Cell Leukemia, etc.)
- Myelodysplastic Syndromes (MDS)
- Myeloproliferative Neoplasms (MPN)
- Others (Overlap Myeloid Neoplasms (MDS/MPN), etc.)
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Pediatric
- Adult
- Geriatric
- By Treatment Modality Insights (Revenue, USD Bn, 2021 - 2033)
- Conventional chemotherapy
- Alkylating agents
- Antimetabolites
- Others (Anthracyclines, etc.)
- Targeted therapies
- Tyrosine kinase inhibitors (e.g., BCR-ABL inhibitors)
- BCL-2 inhibitors
- BTK inhibitors
- Others (PI3K inhibitors, etc.)
- Immunomodulatory drugs (IMiDs)
- Proteasome inhibitors
- Epigenetic / differentiation agents
- Monoclonal antibodies
- Bispecific antibodies / T-cell engagers
- Others (Antibody-drug conjugates (ADCs), etc.)
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Intravenous (IV)
- Subcutaneous (SC)
- Others (Intramuscular (IM), etc.)
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Online
- Offline
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Cancer Centers
- Ambulatory infusion centers
- Homecare Settings
- Others (Academic and Research Institutes, etc.)
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Bristol-Myers Squibb
- Roche
- Novartis
- AbbVie
- Amgen
- Celgene
- Gilead Sciences
- Johnson & Johnson
- Sanofi
- Merck & Co.
- Pfizer
- Eli Lilly and Company
- Takeda Pharmaceutical Company
- GSK
- Regeneron Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Hematologic Malignancies Market, By Type
- Global Hematologic Malignancies Market, By Age Group
- Global Hematologic Malignancies Market, By Treatment Modality
- Global Hematologic Malignancies Market, By Route of Administration
- Global Hematologic Malignancies Market, By Distribution Channel
- Global Hematologic Malignancies Market, By End User
- Global Hematologic Malignancies Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Hematologic Malignancies Market, By Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Acute Leukemias
- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Leukemias
- Chronic Myeloid Leukemia (CML)
- Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
- Others (Hairy Cell Leukemia, etc.)
- Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma (NHL)
- Plasma Cell Dyscrasias
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Multiple Myeloma
- Smoldering Multiple Myeloma
- Others (Plasma Cell Leukemia, etc.)
- Myelodysplastic Syndromes (MDS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Myeloproliferative Neoplasms (MPN)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others (Overlap Myeloid Neoplasms (MDS/MPN), etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Hematologic Malignancies Market, By Age Group, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Hematologic Malignancies Market, By Treatment Modality, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Conventional chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Alkylating agents
- Antimetabolites
- Others (Anthracyclines, etc.)
- Targeted therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Tyrosine kinase inhibitors (e.g., BCR-ABL inhibitors)
- BCL-2 inhibitors
- BTK inhibitors
- Others (PI3K inhibitors, etc.)
- Immunomodulatory drugs (IMiDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Proteasome inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Epigenetic / differentiation agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Monoclonal antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Bispecific antibodies / T-cell engagers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others (Antibody-drug conjugates (ADCs), etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Hematologic Malignancies Market, By Route of Administration, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Intravenous (IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Subcutaneous (SC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others (Intramuscular (IM), etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global Hematologic Malignancies Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Online
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Offline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
9. Global Hematologic Malignancies Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Cancer Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Ambulatory infusion centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others (Academic and Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
10. Global Hematologic Malignancies Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celgene
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GSK
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
